Navigation Links
Medpace Director of Clinical Pharmacology, Jim Wei, MD, PhD, Embarks on a Regulatory Policy Speaking Tour in China in May
Date:5/5/2008

CINCINNATI, May 5 /PRNewswire/ -- Medpace, a leading global full-service contract research organization, announced that Jim Wei, MD, PhD, Medpace Director of Clinical Pharmacology, will address three international conferences in China in May. He will speak at the Impact China IV Conference in Beijing, at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, and at the International Society for the Study of Xenobiotics in Shanghai.

At the Impact China IV Conference in Beijing, China on 4-6 May, Dr. Wei will speak on "The Role of Foreign Data and FDA Requirements." In his presentation he will discuss how both pre-clinical and clinical data from foreign countries has increased in Investigational New Drug Application (IND), New Drug Application (NDA), and Biologic License Application (BLA) submissions in the US.

Dr. Wei will talk about "Current FDA Policy and Opportunities for the Chinese Pharmaceutical Industry" at the International Workshop on Mass Spectrometry and New Drug Development in Hangzhou, China on 8-10 May. In his presentation Dr. Wei will discuss regulatory policies that would help Chinese generic suppliers and the opportunities for botanical drug products in the US market.

At the Second Asian Pacific Regional Meeting of the International Society for The Study of Xenobiotics, held in Shanghai, China on 11-13 May, Dr. Wei will speak on the "Current US FDA Recommendations on Drug Interaction Studies and Challenges to the Pharmaceutical Industry." In this presentation he will reveal the challenges to the pharmaceutical industry -- the requirement of the knowledge level of drug metabolism and drug interactions, optimal design of in vitro and in vivo studies, and integrated analyses to assess the risk/benefit ratio of new drugs for potential harmful drug interactions.

Dr. Wei joined Medpace in November 2007 with extensive experience in the clinical trial regulatory aspects of early phase studies. He came to Medpace from the FDA where he served as a Senior Reviewer in the Office of Clinical Pharmacology and was also heavily involved in reviewing INDs and NDAs for the Division of Metabolism and Endocrinology Products.

ABOUT MEDPACE

Medpace is a leading global full-service contract research organization led by top therapeutic and regulatory experts who are driven to further the advancement of pharmaceutical agents for use in cardiology, metabolism, and oncology. Medpace has assembled the industry's most experienced and therapeutically focused team to execute at every level of the company's operations, providing complete and seamless drug development services.

Through specialized regulatory expertise and therapeutically focused clinical operations, Medpace creates strategic partnerships with pharmaceutical and biotechnology companies to provide the most efficient and cost-effective path to drug development -- from program planning and execution to product approval.

With more than 700 employees and clinical trial experience in over 40 countries, Medpace has the global reach and capability to conduct studies and navigate regulatory requirements worldwide within the core therapeutic areas of cardiology, metabolism, and oncology.

Medpace provides centralized image management and reading from Imagepace, centralized laboratory and therapeutically specialized testing from Medpace Reference Laboratories, and Phase I / IIa research services from Medpace Clinical Pharmacology.
Visit the Medpace website at http://www.medpace.com

Contact: John Wynne, 513-579-9911, x2407

j.wynne@medpace.com


'/>"/>
SOURCE Medpace, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Facet Solutions, Inc. Appoints Industry Veteran to Board of Directors
2. Phyhealth Appoints Gerald H. Priceman as Medical Director
3. Halleland Health Consulting Hires New Director of Lifescience Business Development Peter T. Bianco
4. NightHawk Radiology Holdings, Inc. Announces Appointment of David Engert to the Board of Directors
5. Seattle-Based Marsha Rivkin Center for Ovarian Cancer Research Appoints Nancy Sclater, Executive Director
6. Allen Kukovich, Director, Governors Southwest PA Office, Joins Call for Quality Affordable Health Insurance
7. Mentice, Inc. Expands Its North American Sales and Clinical Presence With the Hiring of Jeff Sirek as Director of Educational Sales-East and Sue Landsman as Clinical Applications Manager for the Americas.
8. Executive Director of cbm US congratulates UN on Malaria Campaign
9. Lotus Pharmaceuticals, Inc. Announces Resignation of Director Mel Rothberg
10. US Oncology Welcomes New Director of Federal Government Relations
11. Steris Corporation Announces the Appointment of Two New Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San ... using cutting-edge Oventus O2Vent technology. As many as 18 million Americans are ... cessation in breathing. Oral appliances can offer significant relief to about 75 percent ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... system that we intend to develop to enable prevention of a major side ... severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss is FDA ...
(Date:10/12/2017)... ... ... Leading pediatric oncology experts at Children’s National Health System will join ... International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by Jeffrey Dome, ... at Children’s National, and Stephen P. Hunger, M.D., Chief of the Division of ...
(Date:10/12/2017)... ... October 12, 2017 , ... Health ... interactive health literacy software tool, and the Cancer Patient Education Network (CPEN), an ... education, today announce a new strategic alliance. , As CPEN’s strategic partner, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, ... formed by Walgreens and pharmacy benefit manager Prime Therapeutics ... new brand, which included the unveiling of new signage ... , as well as at a few other company-owned ... new brand to patients, some of whom will begin ...
(Date:9/27/2017)... , Sept. 27, 2017  Commended for their devotion ... notable awards. Ranked as number one in the South Florida ... time in Inc. 5000 yearly list, the national specialty pharmacy ... Armando Bardisa will soon be honored by SFBJ ... Set to receive his award in ...
(Date:9/22/2017)... 2017  As the latest Obamacare repeal effort moves ... (R-LA) and Lindsey Graham (R-SC) medical ... device industry is in an odd place.  The industry ... excise tax on medical device sales passed along with ... patients, increased visits and hospital customers with the funding ...
Breaking Medicine Technology: